Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
GSK collaboration extension and new data licensing agreement with 23andMe
We advised GSK on the transaction
IDEAYA Biosciences $143.8 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Aligos Therapeutics $92 million private placement
The PIPE included common stock and warrants
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction
Roivant Sciences registered direct offering and investment in Immunovant
We advised Roivant on the transactions
Inventiva $58 million at-the-market offering
The American depositary shares are listed on Nasdaq
HilleVax $115 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
RayzeBio $358 million IPO
The stock is listed on the Nasdaq Global Market
Natera $250 million follow-on offering
The shares are listed on the Nasdaq Global Select Market